Akèy › Timè nan sèvo › North Carolina › Durham
Etid klinik pou Timè nan sèvo nan Durham, NC
14 etid pou Timè nan sèvo ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Duke University School of Medicine, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0100, Durham
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Duke Cancer Institute, Durham
Targeted Pediatric High-Grade Glioma Therapy
Ap rekriteEtid obsèvasyon
- Duke University Health System, Durham
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Ap rekriteFaz 2
- Duke University, Durham
Study of Olutasidenib and Temozolomide in HGG
Ap rekriteFaz 2
- Duke University Health System, Durham
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
Ap rekriteFaz 1
- Duke University Medical Center, Durham
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
Ap rekriteEtid obsèvasyon
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10 mi lwen
B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy
Ap rekrite
- Duke University Medical Center, Durham
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ap rekriteFaz 2
- Duke University Health System, Durham
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Ap rekriteFaz 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Key Longitudinal Associations With Risk and Glioblastoma Outcomes
Ap rekriteEtid obsèvasyon
- Duke University, Durham
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
Ap rekriteEtid obsèvasyon
- Duke Cancer Center, Durham
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Etid Timè nan sèvo nan lòt vil
- Houston, TX35 etid
- Boston, MA28 etid
- New York City, NY25 etid
- Washington, DC20 etid
- Los Angeles, CA16 etid
- Miami, FL15 etid
- St. Louis, MO12 etid
- Cleveland, OH11 etid
- Seattle, WA11 etid
- Rochester, MN11 etid
- Baltimore, MD11 etid
- Columbus, OH11 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè poumon32 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Lukemi lenfositè kwonik27 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.